Suresh S. Ramalingam, MD, on Non–Small Cell Lung Cancer: Pemetrexed, Bevacizumab, or Both as Maintenance Therapy
2019 ASCO Annual MeetingSuresh S. Ramalingam, MD, of Winship Cancer Institute, Emory University, discusses findings from the ECOG-ACRIN 5508 study, which showed that single-agent bevacizumab or pemetrexed is the optimal maintenance therapy for advanced nonsquamous NSCLC (Abstract 9002).
Related Videos
Margaret A. Tempero, MD, on Pancreatic Cancer: Adjuvant Nab-paclitaxel and Gemcitabine
Margaret A. Tempero, MD, discusses phase III results from the multicenter APACT trial, which showed that adjuvant nab-paclitaxel plus gemcitabine may be an option for patients who ...
Michael J. Morris, MD, on Metastatic Prostate Cancer: Adding Abiraterone Acetate to Enzalutamide
Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses the phase III findings from the Alliance A031201 trial, which showed that adding abiraterone aceta...
Gilberto Lopes, MD, MBA, on the RELAY Trial in Metastatic NSCLC: Erlotinib and Ramucirumab in EGFR Mutant–Positive Disease
Gilberto Lopes, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, offers commentary on phase III findings from the RELAY study, which showed that er...
Thomas J. George, MD, on Locally Advanced Rectal Cancer: Total Neoadjuvant Therapy
Thomas J. George, MD, of NRG Oncology and The University of Florida Health Cancer Center, discusses the initial phase II results from a clinical trial using total neoadjuvant...
Jame Abraham, MD, on NALA Trial Findings in HER2-Positive Metastatic Breast Cancer
Jame Abraham, MD, of the Cleveland Clinic, provides commentary on the NALA study findings on neratinib plus capecitabine vs lapatinib plus capecitabine in patients previously...
